Biden vs. Pharma: ‘You Come For The King…’
The president’s state of the union address comes after a year of mostly disappointing efforts for the administration on COVID and drug pricing.
You may also be interested in...
Revlimid was the driving force behind Celgene’s growth, but also became symbolic in the ongoing row over US drug prices.
Three new guidances were announced the morning of President Biden’s State of the Union address, but experts said the move did not equate with past White House pressure on agency decisions.
When the Democratic party regained control of the US House of Representatives in 2019, their push to enact comprehensive drug pricing legislation began with a hearing on insulin. After four years, it might be ending with insulin as the sole focus after all.